IP Library Granted Patent US 8,212,009
Granted Patent B2
US 8,212,009 · App. 12/545,731 · Granted Jul 3, 2012

Methods and compounds for lymphoma cell detection and isolation

Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,212,009
App. No.
12/545,731
Granted
Jul 3, 2012
Kind
B2
Abstract

Compositions comprising a purified and/or isolated antibody, humanized antibodies, precipitates and anti-sera that specifically bind to or are otherwise directed against ROR1 protein. The compositions may be used for detecting ROR1 in a sample from a subject that is suspected or known to contain cancer cells. The ROR1 antibodies are especially useful in identifying and treating lymphomas and ademocarcinomas. Vaccines and related methods for protecting a subject against diseases that involve expression of ROR1 are also provided, as are human anti-sera effective in abrogating interactions between Wnt5a protein and ROR1 that contribute to the survival of certain cancer cells, such as CLL cells.

Claims (9)

1. An isolated antibody that specifically binds ROR1 protein, wherein the antibody comprises the VH chain sequence of SEQ ID NO:3 and the VL chain sequence of SEQ ID NO:6.

2. The antibody of claim 1 , wherein the antibody specifically binds ROR1 protein with a dissociation constant of below a Kd value selected from the group consisting of 10 −6 mol/l, 10 −7 mol/l, and 10 −8 mol/l.

3. The antibody of claim 1 , wherein the ROR1 protein is encoded by the nucleotide sequence of SEQ ID NO: 1.

4. The antibody of claim 1 , wherein the ROR1 protein comprises the amino acid sequence as set forth in SEQ ID NO: 2.

5. The antibody of claim 1 , wherein the antibody is humanized.

6. The antibody of claim 1 , wherein the antibody is a functional antibody fragment.

7. The antibody of claim 1 , wherein the antibody is chimeric.

8. The antibody of claim 1 , wherein the antibody is selected from the group consisting of whole antibody, Fab fragment, Fab′ fragment, F(ab′) 2 fragment, single chain Fv fragment and diabody.

9. The antibody of claim 1 , wherein the antibody is detectably labeled.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 22, 2012
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028826/0427 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2010
From: KIPPS, THOMAS J.; FUKUDA, TETSUYA; ENDO, TOMOYUKI; ZHANG, SUPING; CHEN, LIGUANG; BROOME, H. ELIZABETH
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 023958/0646 →
Continuity (6)
Continuation In Part PCTUS2008054613 · Feb 21, 2008
Continuation In Part PCTUS2006042689 · Oct 30, 2006
Provisional Application 60971818 · Sep 12, 2007
Provisional Application 60731210 · Oct 28, 2005
Provisional Application 61099149 · Sep 22, 2008
Related Publication 20100062005A1 · Mar 11, 2010